Rigel Pharmaceuticals, Inc. (RIGL)

Market Cap	539.71M +59.8%
Revenue (ttm)	299.77M +47.6%
Net Income	364.23M +879.7%
EPS	18.95 +809.5%
Shares Out	18.50M
PE Ratio	1.54
Forward PE	7.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	441,631
Open	29.17
Previous Close	29.01
Day's Range	28.51 - 29.34
52-Week Range	18.14 - 52.24
Beta	1.20
Analysts	Buy
Price Target	53.20 (+82.38%)
Earnings Date	May 5, 2026

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test;...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 29, 2000
• Employees: 174
• Stock Exchange: NASDAQ
• Ticker Symbol: RIGL
• Website: https://www.rigel.com

Financial Performance

In 2025, Rigel Pharmaceuticals's revenue was $294.28 million, an increase of 64.15% compared to the previous year's $179.28 million. Earnings were $367.02 million, an increase of 1999.08%.

Analyst Summary

According to 5 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price target is $53.2, which is an increase of 82.38% from the latest price.

Price Target

$53.2

(82.38% upside)

Analyst Consensus: Buy